The FDA has expanded the indication for the Orbis Paxman Hair Loss Cooling System to prevent chemotherapy-related alopecia in patients with solid tumors.
Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.
The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.
Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner is a pioneer in the treatment of older patients with cancer.
Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.
The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.
Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.
The FDA has approved intravenous rolapitant for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting in adults.
Biocon has announced that the FDA has issued a complete response letter for Mylan’s biologics License Application for MYL-1401H, a proposed biosimilar for Amgen’s pegfilgrastim (Neulasta).
The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD.